Video

Institutional Perspectives in Cancer- Lung Cancer: Chaired by Jason Porter, MD

Institutional Perspectives in Cancer- Lung Cancer: Chaired by Jason Porter, MD

The live filming of this virtual event in our IPC series is now on-demand.

OncLive is proud to present the State of the Science Summits and a new virtual event, Institutional Perspectives in Cancer (IPC). Each summit and webinar will convene for a short meeting designed to educate healthcare professionals on the clinical benefits associated with new science driving new thinking in cancer management. Attendees will not only improve their knowledge of novel treatment approaches, but also leave the event the with confidence and intent to apply state-of-the-art treatment strategies to care for their patients. Each event is dedicated to the latest research in one of the following therapeutic areas: Breast Cancer, Lung Cancer, GU & Prostate Cancer, Hematology, or Melanoma.

The State of the Science Summits and IPC assemble academic and community-based physicians & healthcare professionals across key disciplines from medical and surgical oncology. Specialist experts serve as faculty for these premier and renowned oncology summits, which focus on the most relevant cancer topics to ultimately improve patient care.

Speakers 

  • Devika Das, MD | UAB Medicine
  • Jason Porter, MD | West Cancer Center & Research Institute
  • Wade Iams, MD | Vanderbilt University Medical Center
  • Melissa Johnson, MD | Sarah Cannon Research Institute

Topics

  • Frontline Immunotherapy for NSCLC
  • Current Management of SCLC
  • EGFR and Exon-20 Therapies
  • Targeted Therapy for NSCLC

Interested in virtually attending an IPC event? Click here to register for an upcoming webinar.

Some of the episodes from our podcast, OncLive On Air, are focused on the interviews with faculty conducted at the State of the Science SummitsClick here to listen to our latest episodes!

Related Videos
5 KOLs are featured in this peer exchange
5 KOLs are featured in this peer exchange
Osimertinib (osi) after definitive chemoradiotherapy (CRT) in patients (pts) with unresectable stage (stg) III epidermal growth factor receptor-mutated (EGFRm) NSCLC: Primary results of the phase 3 LAURA study
Zofia Piotrowska, MD, MHS, and Martin Dietrich, MD, PhD, experts on lung cancer
Five-year outcomes with first-line (1L) nivolumab + ipilimumab + chemotherapy (N + I + C) vs C in patients (pts) with metastatic NSCLC (mNSCLC) in CheckMate 9LA
Benjamin Levy, MD
Lorlatinib vs Crizotinib in Treatment-Naive Patients With Advanced ALK+ Non-Small Cell Lung Cancer: 5-Year Progression-Free Survival and Safety From the CROWN Study
Chinmay Jani, MD, clinical fellow, Hematology & Oncology, Sylvester Comprehensive Cancer Center at the University of Miami/Jackson Memorial Hospital
Zofia Piotrowska, MD, MHS, and Martin Dietrich, MD, PhD, experts on lung cancer
Zofia Piotrowska, MD, MHS, and Martin Dietrich, MD, PhD, experts on lung cancer